(NASDAQ: NXTC) Nextcure's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.
Nextcure's earnings in 2026 is -$55,844,000.On average, 5 Wall Street analysts forecast NXTC's earnings for 2026 to be -$29,864,007, with the lowest NXTC earnings forecast at -$30,739,868, and the highest NXTC earnings forecast at -$28,711,146. On average, 3 Wall Street analysts forecast NXTC's earnings for 2027 to be -$12,601,715, with the lowest NXTC earnings forecast at -$12,107,530, and the highest NXTC earnings forecast at -$12,972,354.
In 2028, NXTC is forecast to generate -$12,129,605 in earnings, with the lowest earnings forecast at -$11,653,934 and the highest earnings forecast at -$12,486,358.